Financial PerformanceNet loss per share was reported at $0.17, missing the consensus estimate of $0.15.
Safety ConcernsThere were three discontinuations in Cohort 3 due to injection site reactions, abdominal pain/diarrhea, and administrative issues such as trial site closure.
Stock PerformanceThe stock has traded down significantly by 28% compared to the XBI index, which gained 1%.